|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amie Gehris explains how IERs solve various pharmaceutical formulation issues, including decreasing the bitter taste of many pharmaceutical drugs, improving patient outcomes by supporting compliance to treatment regimens, and providing new revenue streams for pharmaceutical companies.
|
|
|
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
|
|
|
David K. Lyon, PhD, discusses how low aqueous solubility NCEs have come to define the innovative pharmaceutical pipelines and how advanced technologies are often required to overcome this issue.
|
|
|
Liliana Miinea, PhD, says with certain polymers, it is possible for drug formulators to take full advantage of the benefits of ASDs, enabling them to overcome formulation challenges to deliver more effective novel drug products capable of transforming the lives of patients.
|
|
|
|
|
|
|
|
|

Phosphorex, a leading CDMO located just 26.2 miles from Boston in Hopkinton, MA. Our state-of-the-art facility spans at 30,000 Sq. Ft., with an additional 12,000 Sq. Ft. of cGMP space set to come online in 2024. With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Click here for more.
|
|
|
|
|
|
 |
|
Kindeva Drug Delivery recently announced it has acquired Summit Biosciences Inc., an intranasal drug delivery contract development and manufacturing organization, from its founding….
|
|
 |
|
Credence MedSystems recently announced it has successfully completed Factory Acceptance Testing (FAT) for production of its Companion® injection device platform on the company’s new Clinical Assembly Line…..
|
|
 |
|
Bora Pharmaceuticals Co., Ltd. recently announced its Board of Directors has approved the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer based in Minnesota, US, from shareholders, Sawai….
|
|
 |
|
Abzena has launched AbZelect and AbZelectPRO cell line development (CLD) platforms for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins. The platforms will….
|
|
|
|
|
|
|
|
 |
|
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
|
|
 |
|
Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on
|
|
 |
|
In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….
|
|
|
|
|
|
|
|
 |
|
Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical ingredients (APIs) can, however, create a challenge for flowability and compressibility, and, as a result, …
|
|
 |
|
This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …
|
|
 |
|
Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …
|
|
 |
|
Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …
|
|
|
|
|
Upcoming eNewsletter Features:
January 31 – Analytical Testing
February 7 – Injection Devices
|
|
|
|
|
|
|
|